Sarepta Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was €2,966 Mil.
During the past 12 months, Sarepta Therapeutics's average Total Assets Growth Rate was 55.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 14.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 24.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 47.60% per year.
During the past 13 years, Sarepta Therapeutics's highest 3-Year average Total Assets Growth Rate was 92.80%. The lowest was -6.90%. And the median was 30.10%.
The historical data trend for Sarepta Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sarepta Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (STU:AB3A) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sarepta Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sarepta Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Sarepta Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarepta Therapeutics (STU:AB3A) Business Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:AB3A has been successfully added to your 